Amundi
PNT

Amundi’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Amundi’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,829
Closed -$40.7K – 2152
2023
Q1 		$40.7K Hold
5,829
– – ﹤0.01% 1905
2022
Q4 		$42.3K Buy
+5,829
New +$43.3K ﹤0.01% 1724

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amundi's PNT Position: Q2 2023 in Review

Amundi sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q2 2023, closing a stake of 5,829 shares — an estimated $40.7K sold.

Amundi first reported a position in PNT in Q4 2022 and held it in 2 quarters. The position peaked at $42.3K in Q4 2022. 130 funds tracked by Wall St. Rank hold PNT as of Q2 2023.

  • Amundi reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Amundi sold 5,829 POINT Biopharma Global Inc. Common Stock shares in Q2 2023, an estimated $40.7K.
  • Amundi first reported a position in POINT Biopharma Global Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Amundi's POINT Biopharma Global Inc. Common Stock position peaked at $42.3K in Q4 2022.
  • 130 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q2 2023.

Based on Amundi's 13F filing for Q2 2023, filed 14 Aug 2023.